Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Participants lost 16.7% of baseline weight over 64 weeks, matching clinical trial outcomes despite using half the typical drug dose
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously a mechanism that may offer more pronounced hepatic benefits than existing agents such as semaglutide or tirzepatide
As such, its thought that irregular dosing of GLP-1s may in some cases create or worsen hypoglycemia
JANUMET XR JANUMET XR tablets combine two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in adults with type 2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin extended-release, a member of the biguanide class
Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide
